Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
ANTX - AN2 Therapeutics, Inc.
Market Cap 159.10M P/E - EPS this Y 8.00% Ern Qtrly Grth -
Income -64.73M Forward P/E -2.11 EPS next Y 4.40% 50D Avg Chg 11.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -18.00%
Dividend N/A Price/Book 1.93 EPS next 5Y - 52W High Chg -64.00%
Recommedations 2.40 Quick Ratio 7.64 Shares Outstanding 29.83M 52W Low Chg 68.00%
Insider Own 25.17% ROA -36.07% Shares Float 11.90M Beta -0.05
Inst Own 69.77% ROE -58.83% Shares Shorted/Prior 736.90K/272.51K Price 8.19
Gross Margin - Profit Margin - Avg. Volume 98,716 Target Price 12.00
Oper. Margin - Earnings Date - Volume 8,781 Change -0.12%
Healthcare | Biotechnology | United States
About AN2 Therapeutics, Inc.

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, which is in a pivotal Phase 2/3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease. The company also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials. It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize, or otherwise exploit certain compounds and products, including epetraborole, for the treatment, diagnosis, or prevention of all human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize certain compounds and products, including epetraborole, in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases. The company was incorporated in 2017 and is headquartered in Menlo Park, California.

AN2 Therapeutics, Inc. News
05/14/24 AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights
03/28/24 AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights
02/22/24 13 Best Falling Stocks To Buy Right Now
02/12/24 UPDATE 1-AN2 Therapeutics to pause lung disease study enrollment
02/12/24 AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease
02/01/24 We're Not Very Worried About AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Rate
01/30/24 AN2 Therapeutics to Present at Oppenheimer Healthcare Life Sciences Conference
01/12/24 AN2 Therapeutics Inc Chief Strategy Officer Kevin Krause Sells 7,417 Shares
01/10/24 Recent Price Trend in AN2 Therapeutics, Inc. (ANTX) is Your Friend, Here's Why
11/12/23 One AN2 Therapeutics Insider Raised Their Stake In The Previous Year
11/09/23 AN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific Highlights
11/06/23 AN2 Therapeutics, Inc. (ANTX) Is a Great Choice for 'Trend' Investors, Here's Why
11/06/23 AN2 Therapeutics to Present at Upcoming Investor Conferences
10/18/23 AN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas Disease
05:43 AM AN2 Therapeutics, Inc. (NASDAQ:ANTX) stock most popular amongst individual investors who own 29%, while private equity firms hold 27%
10/10/23 AN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023
09/27/23 Is Adagene (ADAG) Outperforming Other Medical Stocks This Year?
09/26/23 AN2 Therapeutics Signs Grant Agreement to Discover Novel, Boron Based Therapies for Tuberculosis and Malaria
09/13/23 AN2 Therapeutics commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium complex (MAC) Lung Disease
09/11/23 Has AN2 Therapeutics (ANTX) Outpaced Other Medical Stocks This Year?
ANTX Chatroom

User Image AnaChart Posted - 9 hours ago

$ANTX https://anachart.com/wp-content/uploads/ana_temp/1715875312_soc-img.jpg

User Image i_like_bb_stock Posted - 1 day ago

$ANTX took some here https://twitter.com/TradeHawk/status/1790779082696962142

User Image TradeHawk Posted - 1 day ago

$ANTX AN2 Therapeutics has been awarded a $3.8 million National Institutes of Health contract option for development of Epetraborole as a novel therapeutic for melioidosis and additional antimicrobial resistant bacterial biothreat pathogens. https://www.fpds.gov/ezsearch/jsp/viewLinkController.jsp?agencyID=7529&PIID=75N93022C00059&modNumber=P00004&transactionNumber=0&idvAgencyID=&idvPIID=&actionSource=searchScreen&actionCode=&documentVersion=1.5&contractType=AWARD&docType=D

User Image DonCorleone77 Posted - 2 days ago

$ANTX AN2 Therapeutics reports Q1 EPS (56c), consensus (62c) "The Phase 2 topline data, expected to be available in August, will include the first clinical efficacy data for epetraborole in patients with treatment-refractory MAC. The patients enrolled in EBO-301 are highly refractory with limited to no treatment options; and background regimens available provide little if any benefit," said Eric Easom, Co-Founder, President and Chief Executive Officer. "We hope to see data demonstrating that epetraborole on top of background therapy will show benefit in these toughest to treat patients. The Phase 2 data package will be critical to informing the path forward for epetraborole in patients with treatment refractory MAC."

User Image Stock_Titan Posted - 2 days ago

$ANTX AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights https://www.stocktitan.net/news/ANTX/an2-therapeutics-reports-first-quarter-2024-financial-results-and-zcqzjekpdpxq.html

User Image Redposition Posted - 2 days ago

$ANTX Any news about earning date ? Thank you !

User Image David555 Posted - 1 week ago

$ANTX Zacks just upgraded to buy https://www.zacks.com/stock/quote/ANTX

User Image Evo13 Posted - 1 week ago

$ANTX this is rising slowly and no one paying attention

User Image Mitcheski_R3surrected Posted - 04/25/24

$ANTX will DCA at .75

User Image TrendSurfer21 Posted - 04/25/24

$ANTX amazing chart… scaling in here

User Image Uranus713 Posted - 04/24/24

$ANTX solid Boeing BA option put for 162.5 I believe in Boeing company 😇

User Image Uranus713 Posted - 04/24/24

$ANTX 1.75 ℹ will be buying more 100. I wish they had options. 🫣

User Image Mitcheski_R3surrected Posted - 04/22/24

$ANTX is 1.50 bottom?

User Image Camelinvesting Posted - 1 month ago

$ANTX still undervalued. Watching closely

User Image Mitcheski_R3surrected Posted - 1 month ago

$ANTX ouch 🤕

User Image Redposition Posted - 1 month ago

$ANTX Why going down ? Any news ?

User Image Uranus713 Posted - 1 month ago

$ANTX added some for 2.75

User Image Mitcheski_R3surrected Posted - 1 month ago

$ANTX bottom is 1.88

User Image Mitcheski_R3surrected Posted - 1 month ago

$ANTX why did I buy at 3.50 🤦‍♂️

User Image MaverikIT Posted - 1 month ago

@net0trader @DonCorleone77 @Cash4freedom @Im_not_Mr_Lebowski @Wigglyick @IsabellaDC @RonIsWrong $ANET - da 'daady' of $CSCO $SMCI $NVDA $ANTX

User Image ElonRMusk Posted - 1 month ago

$ANTX mega volume spike today, but price didn't move. Was this an arranged sale?

User Image _www_larval_com_ Posted - 1 month ago

$ANTX has stumbled -3% lower to 0% (~1Mv) a moment ago, follow for more volatility.

User Image TrendSurfer21 Posted - 1 month ago

$ANTX moving nicely

User Image Mitcheski_R3surrected Posted - 1 month ago

$ANTX is this for real?

User Image TrendSurfer21 Posted - 1 month ago

$ANTX hello beauty… 🤔🙇‍♂️😋

User Image Boomer52 Posted - 1 month ago

$ANTX 24% drop in three days

User Image GSMITH10107 Posted - 1 month ago

$ANTX $ANTX most undervalued cash rich biotech with a late stage drug i can find.. this one is far from dead.. risky? yes.. they still plan to go on with phase 3 but need to discuss with governing bodies on next steps.. potential multibagger imo

User Image Mitcheski_R3surrected Posted - 1 month ago

$ANTX will be an exciting volume tomorrow

User Image GSMITH10107 Posted - 1 month ago

$ANTX 130million in cash and 14 million in liabilities lol with multiple shots on goal?

User Image Mitcheski_R3surrected Posted - 1 month ago

$ANTX wow it was just april fools? I bought a lot tho :/

Analyst Ratings
Evercore ISI Group In-Line May 16, 24
JMP Securities Market Outperform Apr 2, 24
Oppenheimer Perform Apr 1, 24
Leerink Partners Market Perform Feb 13, 24
Evercore ISI Group In-Line Feb 12, 24
Oppenheimer Perform Feb 12, 24
JMP Securities Market Perform Feb 12, 24
JMP Securities Market Outperform Jan 4, 24
Oppenheimer Outperform Mar 30, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Zakrzewski Joseph S Director Director Jan 18 Sell 19.1141 100,000 1,911,410 405,880 01/19/24
Aziz Kabeer Director Director Jan 16 Sell 19.65 100,000 1,965,000 377,542 01/18/24
Adjuvant Global Health Technol... Director Director Jan 16 Sell 19.65 100,000 1,965,000 377,542 01/18/24
Readnour Robin Shane Director Director Jan 12 Sell 21.92 1,425 31,236 485,073 01/17/24
Readnour Robin Shane Director Director Jan 10 Sell 21.93 3,669 80,461 485,792 01/12/24
Krause Kevin Michael Chief Strategy Offic.. Chief Strategy Officer Jan 09 Sell 20.14 7,417 149,378 1,914 01/11/24
Krause Kevin Michael Chief Strategy Offic.. Chief Strategy Officer Jan 09 Option 3.51 7,417 26,034 9,331 01/11/24
Krause Kevin Michael Chief Strategy Offic.. Chief Strategy Officer Jan 02 Sell 20.12 2,583 51,970 1,914 01/04/24
Krause Kevin Michael Chief Strategy Offic.. Chief Strategy Officer Jan 02 Option 0.42 2,583 1,085 4,497 01/04/24
Easom Eric Chief Executive Offi.. Chief Executive Officer Jan 02 Sell 20.0945 2,777 55,802 2,130 01/04/24
Adjuvant Global Health Technol... Director Director Nov 14 Sell 16.15 1,810 29,231 393,449 11/16/23
Aziz Kabeer Director Director Nov 14 Sell 16.15 1,810 29,231 393,449 11/16/23
Aziz Kabeer Director Director Sep 29 Sell 16.18 104,773 1,695,227 393,737 10/03/23
Adjuvant Global Health Technol... Director Director Sep 29 Sell 16.18 104,773 1,695,227 393,737 10/03/23
Adjuvant Global Health Technol... Director Director Sep 27 Sell 16.09 9,357 150,554 410,403 09/29/23
Aziz Kabeer Director Director Sep 27 Sell 16.09 9,357 150,554 410,403 09/29/23
Aziz Kabeer Director Director Aug 23 Sell 16 400 6,400 411,893 09/15/23
Adjuvant Global Health Technol... Director Director Aug 23 Sell 16 400 6,400 411,893 09/15/23
RA CAPITAL MANAGEMENT, L.P. 10% Owner 10% Owner Aug 18 Buy 9.00 1,777,778 16,000,002 5,135,683 08/22/23
Easom Eric Chief Executive Offi.. Chief Executive Officer May 15 Buy 5.377 10,000 53,770 1,015,766 05/15/23
Easom Eric Chief Executive Offi.. Chief Executive Officer Nov 10 Sell 15.18 4,436 67,338 4,907 11/14/22
Easom Eric Chief Executive Offi.. Chief Executive Officer Nov 08 Sell 15.8 17,166 271,223 4,907 11/09/22
Easom Eric Chief Executive Offi.. Chief Executive Officer Nov 03 Sell 16.02 35,196 563,840 4,907 11/07/22
Easom Eric Chief Executive Offi.. Chief Executive Officer Oct 31 Sell 15.23 4,232 64,453 4,907 11/02/22
Easom Eric Chief Executive Offi.. Chief Executive Officer Oct 27 Sell 15.22 2,607 39,679 4,907 10/28/22
Easom Eric Chief Executive Offi.. Chief Executive Officer Oct 24 Sell 15.79 9,350 147,636 4,907 10/26/22
Easom Eric Chief Executive Offi.. Chief Executive Officer Oct 20 Sell 16.7 21,244 354,775 4,907 10/24/22
RA CAPITAL MANAGEMENT, L.P. 10% Owner 10% Owner Jul 26 Buy 7.81 23,219 181,340 3,771,608 07/28/22
Adjuvant Global Health Technol... 10% Owner 10% Owner Mar 29 Buy 15 166,666 2,499,990 2,210,735 06/24/22
Readnour Robin Shane Director Director Mar 29 Buy 15 153,334 2,300,010 487,592 03/31/22
Aziz Kabeer Director Director Mar 29 Buy 15 166,666 2,499,990 2,210,735 03/31/22